Immunotherapy for Esophageal Squamous Cell Carcinoma

Esophageal squamous cell carcinoma have been frustrating to treat, with slow progress made on extending survival. Immunotherapy targeting immune checkpoints, T cells, and infiltrating lymphocytes has shown promise in early studies. The efficacy of pembrolizumab and nivolumab is encouraging. Anti-che...

Descripción completa

Detalles Bibliográficos
Autores principales: Kojima, Takashi, Doi, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Gastrointestinal Cancers (J Meyer, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374168/
https://www.ncbi.nlm.nih.gov/pubmed/28361224
http://dx.doi.org/10.1007/s11912-017-0590-9
_version_ 1782518843390820352
author Kojima, Takashi
Doi, Toshihiko
author_facet Kojima, Takashi
Doi, Toshihiko
author_sort Kojima, Takashi
collection PubMed
description Esophageal squamous cell carcinoma have been frustrating to treat, with slow progress made on extending survival. Immunotherapy targeting immune checkpoints, T cells, and infiltrating lymphocytes has shown promise in early studies. The efficacy of pembrolizumab and nivolumab is encouraging. Anti-chemokine receptors and oncolytic viruses are also making headway against these stubborn tumors; improved results when immune checkpoint inhibitors are combined with radiation therapy are eagerly anticipated. Adoptive T cell therapy and vaccines are also under development. The importance of a multidisciplinary approach cannot be emphasized enough.
format Online
Article
Text
id pubmed-5374168
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-53741682017-04-12 Immunotherapy for Esophageal Squamous Cell Carcinoma Kojima, Takashi Doi, Toshihiko Curr Oncol Rep Gastrointestinal Cancers (J Meyer, Section Editor) Esophageal squamous cell carcinoma have been frustrating to treat, with slow progress made on extending survival. Immunotherapy targeting immune checkpoints, T cells, and infiltrating lymphocytes has shown promise in early studies. The efficacy of pembrolizumab and nivolumab is encouraging. Anti-chemokine receptors and oncolytic viruses are also making headway against these stubborn tumors; improved results when immune checkpoint inhibitors are combined with radiation therapy are eagerly anticipated. Adoptive T cell therapy and vaccines are also under development. The importance of a multidisciplinary approach cannot be emphasized enough. Springer US 2017-03-30 2017 /pmc/articles/PMC5374168/ /pubmed/28361224 http://dx.doi.org/10.1007/s11912-017-0590-9 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Gastrointestinal Cancers (J Meyer, Section Editor)
Kojima, Takashi
Doi, Toshihiko
Immunotherapy for Esophageal Squamous Cell Carcinoma
title Immunotherapy for Esophageal Squamous Cell Carcinoma
title_full Immunotherapy for Esophageal Squamous Cell Carcinoma
title_fullStr Immunotherapy for Esophageal Squamous Cell Carcinoma
title_full_unstemmed Immunotherapy for Esophageal Squamous Cell Carcinoma
title_short Immunotherapy for Esophageal Squamous Cell Carcinoma
title_sort immunotherapy for esophageal squamous cell carcinoma
topic Gastrointestinal Cancers (J Meyer, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374168/
https://www.ncbi.nlm.nih.gov/pubmed/28361224
http://dx.doi.org/10.1007/s11912-017-0590-9
work_keys_str_mv AT kojimatakashi immunotherapyforesophagealsquamouscellcarcinoma
AT doitoshihiko immunotherapyforesophagealsquamouscellcarcinoma

Ejemplares similares